The Cancer Letter
banner
cancerletter.com
The Cancer Letter
@cancerletter.com
The leading independent source for information on the issues that shape oncology since 1973. cancerletter.com
Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer
https://cancerletter.com/clinical/20260123_1/
Premarin’s 84-year hold on the market ends as FDA approves a generic version Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer...
A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in […]
cancerletter.com
January 23, 2026 at 11:00 PM
Over two years, these missed screenings are projected to result in 1,448 undetected breast, 1,026 undetected colorectal, and 738 undetected lung cancers.
https://cancerletter.com/clinical/20260116_2/
New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years - The Cancer Letter
New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month. To access this […]
cancerletter.com
January 22, 2026 at 7:00 PM
"We must widen the front door to early detection as the difference between stage 1 and stage 4 is the difference between cure and control, between hope and heartbreak," writes @cityofhope.bsky.social's Kevin King
https://cancerletter.com/trials-and-tribulations/20260116_4/
A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers - The Cancer Letter
As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,... […]
cancerletter.com
January 22, 2026 at 1:00 PM
“I didn’t take the conventional approach. I decided to develop a new system for isolating antigens,” @roswellpark.bsky.social's Seon said in 2019. “It’s always been in my mind that hopefully someday I could find a new cancer drug, a better cancer drug.”
https://cancerletter.com/obituary/20260116_5/
January 22, 2026 at 1:00 AM
Katie Coleman named senior advisor for translational innovation at OSUCCC—James
https://cancerletter.com/in-brief/20260116_7c/
https://cancerletter.com/in-brief/20260116_7c/
Invalid response status code (0)
cancerletter.com
January 21, 2026 at 12:00 PM
"As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease," writes @cityofhope.bsky.social's Kevin King
https://cancerletter.com/trials-and-tribulations/20260116_4/
A radiation oncologist’s perspective: Why we need to accelerate early detection strategies for lung cancers - The Cancer Letter
As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,... […]
cancerletter.com
January 20, 2026 at 8:00 PM
Ben K. Seon, a senior faculty member and distinguished immunology scientist at @roswellpark.bsky.social across six decades, died Dec. 17, 2025. He was 89.
https://cancerletter.com/obituary/20260116_5/
January 20, 2026 at 3:58 PM
New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years.
https://cancerletter.com/clinical/20260116_2/
New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years - The Cancer Letter
New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month. To access this […]
cancerletter.com
January 20, 2026 at 1:00 PM